Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Leukemia, Myeloid, Acute 7Recurrence 5Colonic Neoplasms 5Thyroid Neoplasms 4Thyroid Diseases 4Thyroid Cancer, Papillary 4Thoracic Neoplasms 4Respiratory Tract Neoplasms 4Respiratory Tract Diseases 4Neuroblastoma 4Neoplasms by Site 4Lung Neoplasms 4Lung Diseases 4Head and Neck Neoplasms 4Endocrine System Diseases 4Endocrine Gland Neoplasms 4Carcinoma, Bronchogenic 4Bronchial Neoplasms 4Breast Neoplasms 4Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Leukemia, Lymphocytic, Chronic, B-Cell 3Central Nervous System Neoplasms 3Carcinoma, Medullary 3Urinary Bladder Neoplasms 2Pancreatic Neoplasms 2

Interventions

revumenib 1Midazolam 1Itraconazole 1Cobicistat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Has announcements × Leukemia, Biphenotypic, Acute × Clear all
NCT04067336 2026-05-13

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1/2 Active not recruiting
263 enrolled 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04065399 2026-03-18

AUGMENT-101

Syndax Pharmaceuticals

Phase 1/2 Recruiting
447 enrolled 2 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡